We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antidotes progress for new oral clotbusters.
- Authors
Dolgin, Elie
- Abstract
The article focuses on development made by several drug firms in the section of antidote for new oral clotbusters. Topics discussed include pursuance of antidote by AstraZeneca for its approved antiplatelet drug Brilinta, release of phase 3 data by Portola Pharmaceuticals on its first-in-class antidote andexanet alfa, and release of results by Boehringer Ingelheim regarding effects of its blood thinning pill Pradaxa. Also presented are views of hematologist Stephan Moll on the same.
- Subjects
ANTIDOTES; ASTRAZENECA PLC; PORTOLA Pharmaceuticals Inc.; BOEHRINGER Ingelheim GmbH; MOLL, Stephan
- Publication
Nature Biotechnology, 2015, Vol 33, Issue 2, p117
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0215-117